Results 61 to 70 of about 15,790 (257)

A rare case of recurrent epidermoid anal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy—case report

World Journal of Surgical Oncology, 2020
Background Anal cancer is a rare cancer with chemoradiation being the mainstay of treatment for locoregional presentation. In North America, the most common subtype is anal squamous cell carcinoma (epidermoid).
Vera Pravong, Alexandre Brind’Amour, Lucas Sidéris, Pierre Dubé, Jean-François Tremblay   +4 more
doaj   +1 more source

Real‐world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer—Analysis of the Prospective Dutch Colorectal Cancer cohort

International Journal of Cancer, Volume 157, Issue 3, Page 513-525, 1 August 2025.
What's new? The treatment landscape of metastatic colorectal cancer has evolved into a continuum of care with guideline recommendations depending on molecular status. However, guidelines are primarily based on the results of randomized clinical trials, which do not fully align with clinical practice.
Sietske C. M. W. van Nassau, Koen Zwart, Frederieke H. van der Baan, Geraldine R. Vink, Marloes A. G. Elferink, Petur Snaebjornsson, Anne M. May, Miriam Koopman, Jeanine M. L. Roodhart   +8 more
wiley   +1 more source

Abnormal DNA Methylation Profile Suggests the Extension of the Clinical Spectrum of the SETD2 ‐Related Disorders to a Syndromic Multiple Tumor Phenotype

American Journal of Medical Genetics Part A, Volume 197, Issue 7, July 2025.
ABSTRACT SETD2 has an essential role in epigenetic regulation. SETD2 pathogenic variants cause neurodevelopmental disorders (SETD2‐NDDs) that most commonly include various degrees of intellectual disability and behavioral disorders, macrocephaly, brain malformations, and generalized overgrowth.
Marie Lucain, Antonio Vitobello, Bekim Sadikovic, Juliette Albuisson, Léa Gaudillat, Martin Chevarin, Julien Maraval, Christel Thauvin‐Robinet, Jennifer Kerkhof, Christophe Philippe, Sophie Nambot, Laurence Faivre   +11 more
wiley   +1 more source

The Registry of Hyperthermic Intraperitoneal Chemotherapy – A Mandatory Step in the Development of this Therapeutic Approach in Romania

Applied Medical Informatics, 2015
Multicenter/institutional studies have been the basis for the confirmation of Hyperthermic Intraperitoneal Chemotherapy as a therapeutic option for selected patients with Peritoneal Surface Malignancies.
Corneliu LUNGOCI, Tudor CĂLINICI, Olga ORĂŞAN, Rareş BOSU, Valentin MUNTEAN, Aurel Ion MIRONIUC   +5 more
doaj  

Albumin-based cancer therapeutics for intraperitoneal drug delivery : a review [PDF]

, 2020
Albumin is a remarkable carrier protein with multiple cellular receptor and ligand binding sites, which are able to bind and transport numerous endogenous and exogenous compounds.
Al Rawahi T, Carlier C, Daugirdas JT, Dedrick RL, Fan R, Flessner MF, Goodman MD, Hartung G, Kragh-Hansen U., Lotze MT, Maltas E, Oseledchyk A, Sjobring U, Sun C, Zhao D   +14 more
core   +2 more sources

Retrospective Study of the Epidemiology, Pathology, and Therapeutic Management in Patients With Mucinous Ovarian Tumors

Technology in Cancer Research & Treatment, 2020
Aim: We sought to determine the epidemiology of mucinous ovarian tumors, the correlation between serum biomarkers and tumor status, and the outcomes of the management in different subtypes of mucinous ovarian tumors in a Chinese surgical cohort. Methods:
Yuanyuan Zhang PhD, Chunmei Li MD, Suiyu Luo MD, Ying Su MD, Xiaoqing Gang MD, Peiyuan Chu MD, JuXin Zhang MD, Henghui Wu MD, Guangzhi Liu PhD   +8 more
doaj   +1 more source

Drain site enterocutaneous fistula after hyperthermic intraperitoneal chemotherapy

JGH Open, 2021
Spontaneous sigmoid colon perforation after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is a rare complication. It is more commonly seen with mitomycin‐based HIPEC. This case study's patient presented with pus discharge at
Navin Kumar, Kanak Lata, Mukur Dipi Ray
doaj   +1 more source

The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma

, 2021
Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy offering long-term survival or even ...
de Hingh, I.,, Deraco, M.,, Glehen, O.,, Govaerts, K.,, Kepenekian, V.,, Kusamura, S.,, Lund University., Lurvink, R.J,, Moran, B.,, PSOGI, Syk, Ingvar,, Van der Speeten, K.,, Villeneuve, L.,   +12 more
core   +1 more source

Targeting PTBP3‐Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis

Advanced Science, Volume 12, Issue 21, June 5, 2025.
The splicing factor PTBP3 promotes COX11 exon skipping, allowing gastric cancer organoids to evade cuproptosis. Antisense oligonucleotide drugs targeting PTBP3‐mediated COX11 alternative splicing, in combination with copper ionophores, promote cuproptosis in organoids, thereby providing a therapeutic approach for gastric cancer peritoneal metastasis ...
Yajing Zhou, Chao Dong, Xiaochun Shen, Pengbo Wang, Tao Chen, Weikang Li, Xiaotong Sun, Peiyuan Li, Chengxiang Xu, Kaipeng Duan, Dongbao Li, Jin Zhou   +11 more
wiley   +1 more source

“Adjuvant” Hyperthermic Intraperitoneal Chemotherapy: A Call to Action [PDF]

Annals of Surgical Oncology, 2016
The highly experienced team of Baratti et al. used hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colorectal cancer at high risk for peritoneal metastases. The literature reports an overall median survival of only 1–2 years for this patient population, even in the setting of contemporary systemic chemotherapy.
John C. McAuliffe, Garrett M. Nash
openaire   +3 more sources